Inger von Bültzingslöwen

Inger von Bültzingslöwen

Auto-generated profile, based on publicly available information

Inger von Bültzingslöwen

Department of Oral Microbiology and Immunology, Institute of Odontology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 August 2003 in Oral Microbiology and Immunology
Verified
Journal Article
Closed access
PDF file
IBI. von Bültzingslöwen
I. von Bültzingslöwen
IAI. Adlerberth
I. Adlerberth
AWA. E. Wold
A. E. Wold
GDG. Dahlén
G. Dahlén
MJM. Jontell
M. Jontell

23 April 2018 in JMIR Research Protocols
Verified
Journal Article
Open access
MBMichael T. Brennan
Michael T. Brennan
BHBengt Hasséus
Bengt Hasséus
AHAllan J Hovan
Allan J Hovan
Judith Evelyn Raber-DurlacherJudith Evelyn Raber-Durlacher
Judith Evelyn Raber-Durlacher
NBNicole Blijlevens
Nicole Blijlevens
IBInger von Bültzingslöwen
Inger von Bültzingslöwen
The oral cavity is a common site of complications related to the cytotoxic effect of high-dose chemotherapy and radiation therapy. Considering our limited understanding of the burden of illness in the oral cavity from various cytotoxic therapies, it is difficult to produce evidence-based, preventive and management protocols. A prospective multicenter study is necessary to collect data on the burden of illness from various cytotoxic regimens. The objectives of this prospective international observational multicenter study in hematopoietic stem cell transplant (HSCT) patients are to establish the nature, incidence and temporal relationship of oral complications related to conditioning regimens (chemotherapy with or without total body irradiation), stem cell transplantation and the immunologic reactions (mainly graft-vs-host-disease) that may follow, and to determine what subjective and objective oral complications related to treatment can predict negative clinical and economic outcomes and reduced quality of life. Adult patients at six study sites receiving full intensity conditioning, reduced intensity conditioning or nonmyeloablative conditioning, followed by autologous or allogeneic hematopoietic stem cell infusion, are included. A pre-treatment assessment includes medical conditions, planned chemo- and radiation therapy regimen, medications, allergies, social history, patient report of oral problems, dental history, subjective oral complaints, objective measures of oral conditions, current laboratory values, dental treatment recommended and untreated dental disease. Starting 1-3 days after hematopoietic stem cell infusion, a bedside assessment is completed 3 days per week until resolution of neutropenia. A patient questionnaire is also completed during hospitalization. Beyond this time, patients with continued oral mucositis or other oral problems are followed 1 day per week in an inpatient or outpatient setting. Additional visits for urgent care for acute oral problems after hospitalization are documented. Autologous transplant patients are being followed up at 100 days (SD 30 days) and at 1 year (SD 30 days) post-transplantation to identify any long-term side effects. Patients treated with allogeneic transplantation are being followed at 100 days (SD 30 days), 6 months (SD 30 days), and 12 months (SD 30 days). The follow-up assessments include cancer response to therapy, current medical conditions, medications, subjective and objective oral findings, quality of life measures and laboratory values. The targeted enrollment is 254 patients who have received HSCT. A total of 260 participants have been enrolled, with 233 (91%) who have received HSCT. We anticipate enrollment of 20-30 additional participants to obtain the sample size of 254 enrolled participants who have received HSCT. The results of the ongoing prospective study will provide a unique dataset to understand the impact of oral complications on patients undergoing HSCT and provide needed evidence for guidelines regarding the management of this patient cohort.

18 May 2023 in PLOS ONE
Verified
Journal Article
Open access
PDF file
KSKristina Skallsjö
Kristina Skallsjö
IBInger von Bültzingslöwen
Inger von Bültzingslöwen
BHBengt Hasséus
Bengt Hasséus
JJJan-Erik Johansson
Jan-Erik Johansson
JÖJenny Öhman
Jenny Öhman
MBMichael T. Brennan
Michael T. Brennan
Despite advances in transplant medicine, prevalence of complications after hematopoietic stem cell transplantation (HSCT) remains high. The impact of pre-HSCT oral health factors on the incidence and severity of complications post-HSCT is poorly understood. The aim of this prospective, observational study was to analyze oral health in patients planned for HSCT. Patients ≥18 years requiring HSCT were included from five sites between 2011–2018. General health, oral findings and patient-reported symptoms were registered in 272 patients. Oral symptoms around disease onset were reported by 43 patients (15.9%) and 153 patients (58.8%) reported oral complications during previous chemotherapy. One third of patients experienced oral symptoms at the oral examination before conditioning regimen and HSCT. In total, 124 (46.1%) patients had dental caries, 63 (29.0%) had ≥one tooth with deep periodontal pockets, 147 (75.0%) had ≥one tooth with bleeding on probing. Apical periodontitis was observed in almost 1/4 and partially impacted teeth in 17 (6.3%) patients. Oral mucosal lesions were observed in 84 patients (30.9%). A total of 45 (17.4%) of 259 patients had at least one acute issue to be managed prior to HSCT. In conclusion, oral symptoms and manifestations of oral disease were prevalent in patients planned for HSCT. The extent of oral and acute dental diseases calls for general oral screening of patients pre-HSCT.

8 January 2021 in Bone Marrow Transplantation
Verified
Journal Article
Open access
PDF file
SLStephanie J.M. van Leeuwen
Stephanie J.M. van Leeuwen
Gordon ProctorGordon Proctor
Gordon Proctor
ALAlexa Laheij
Alexa Laheij
CPC. M. J. Potting
C. M. J. Potting
OSO. Smits
O. Smits
NBN. M. A. Blijlevens
N. M. A. Blijlevens
The aim of this multicentre, longitudinal study was to determine salivary changes in relation to oral mucositis (OM) in multiple myeloma patients following high-dose melphalan and autologous hematopoietic stem cell transplantation (ASCT). Unstimulated and stimulated whole-mouth saliva samples (UWS and SWS) were collected before ASCT, 1×/wk during the hospitalisation phase, and 3 and 12 months post-ASCT. During the hospitalisation period OM was scored 3×/wk (WHO system). Flow rate, pH, total protein concentration (Nanodrop), albumin, lactoferrin, neutrophil defensin-1 (HNP1), total IgA and S100A8/A9 (ELISA) were determined. Mixed models were used to evaluate differences between ulcerative (u)OM (≥2 WHO, n = 20) and non-uOM (n = 31) groups. Until 18 days after ASCT, flow rate, pH, total IgA and HNP1 levels decreased in UWS and/or SWS, while log lactoferrin levels were significantly increased (UWS: p = 0.016 95% CI [0.36, 3.58], SWS: p < 0.001 95% CI [1.14, 3.29]). Twelve months post-ASCT, salivary protein levels were similar to baseline except for log total IgA, which was higher (UWS: p < 0.001 95% CI [0.49, 1.29], SWS: p < 0.001 95% CI [0.72, 1.45]). No differences between uOM and non-uOM groups were observed. Changes in salivary proteins indicated an inflammatory reaction in salivary glands coinciding with mucosal and systemic reactions in response to high-dose melphalan.

26 June 2001 in Oral Oncology
Verified
Journal Article
Closed access
IBI von Bültzingslöwen
I von Bültzingslöwen
MJM Jontell
M Jontell
PHP Hurst
P Hurst
UNU Nannmark
U Nannmark
TKT Kardos
T Kardos

16 November 2023 in Supportive Care in Cancer
Verified
Journal Article
Open access
PDF file
MAMonica Barr Agholme
Monica Barr Agholme
GDGöran Dahllöf
Göran Dahllöf
JTJohan Karlsson Törlén
Johan Karlsson Törlén
AMAlessandra Majorana
Alessandra Majorana
MBMichael T. Brennan
Michael T. Brennan
CHCatherine Hsu Ling Hong
Catherine Hsu Ling Hong
Purpose: Oral mucositis is a common complication for patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) and causes pain and difficulties in functions like eating and swallowing, resulting in lower quality of life and greater need of treatment with opioids and parenteral nutrition. This prospective multicenter study focused on pediatric recipients of HSCT in the neutropenic phase concerning oral complications, timing, severity, and patient experience. Methods: The cohort comprised 68 patients, median age 11.1 years (IQR 6.3) receiving allogeneic HSCT at three clinical sites. Medical records were retrieved for therapy regimens, concomitant medications, oral and dental history, and subjective oral complaints. Calibrated dentists conducted an oral and dental investigation before HSCT. After HSCT graft infusion, study personnel made bedside assessments and patients filled out a questionnaire once or twice a week until neutrophil engraftment. Results: We followed 63 patients through the neutropenic phase until engraftment. 50% developed oral mucositis of grades 2–4. Peak severity occurred at 8–11 days after stem cell infusion. Altogether, 87% had subjective oral complaints. The temporal distribution of adverse events is similar to the development of oral mucositis. The most bothersome symptoms were blisters and oral ulcerations, including mucositis; 40% reported severe pain and major impact on activities of daily living despite continuous use of opioids. Conclusion: This study highlights the burden of oral complications and their negative effect on the health and quality of life of HSCT recipients.